Literature DB >> 21819633

Pharmaceutical lobbying under postcommunism: universal or country-specific methods of securing state drug reimbursement in Poland?

Piotr Ozierański1, Martin McKee, Lawrence King.   

Abstract

This paper aims to fill in the gap in research on the effect of pharmaceutical lobbying on drug reimbursement policy, particularly in Poland, a post-communist country. To this end, we conducted in-depth, semi-structured, anonymous, elite interviews in Poland, supplemented by a review of legislation, policy documents, official reports and press articles, as well as observations. Overall, 109 representatives of stakeholders involved in reimbursement policy were interviewed. We identified two key lobbying methods: informal persuasion and third-party endorsements. These methods are coupled with two supplementary ones: lobbying through parliament and ministries, as well as diplomatic pressure. Pharmaceutical lobbying methods in Poland clearly resemble those used in other European countries. What is notable about the Polish case is extensive reliance on informal lobbying and diplomatic pressure.

Mesh:

Year:  2011        PMID: 21819633     DOI: 10.1017/S1744133111000168

Source DB:  PubMed          Journal:  Health Econ Policy Law        ISSN: 1744-1331


  6 in total

1.  Polish physicians' cooperation with the pharmaceutical industry and its potential impact on public health.

Authors:  Marta Makowska
Journal:  PLoS One       Date:  2017-09-19       Impact factor: 3.240

2.  Identifying Patient Access Barriers for Tumor Necrosis Factor Alpha Inhibitor Treatments in Rheumatoid Arthritis in Five Central Eastern European Countries.

Authors:  András Inotai; Dominik Tomek; Maciej Niewada; László Lorenzovici; Martin Kolek; Jakub Weber; Anne-Katrin Kurrat; Emese Virág Kiss; Zoltán Kaló
Journal:  Front Pharmacol       Date:  2020-06-05       Impact factor: 5.810

3.  Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs.

Authors:  Rickard E Malmström; Brian B Godman; Eduard Diogene; Christoph Baumgärtel; Marion Bennie; Iain Bishop; Anna Brzezinska; Anna Bucsics; Stephen Campbell; Alessandra Ferrario; Alexander E Finlayson; Jurij Fürst; Kristina Garuoliene; Miguel Gomes; Iñaki Gutiérrez-Ibarluzea; Alan Haycox; Krystyna Hviding; Harald Herholz; Mikael Hoffmann; Saira Jan; Jan Jones; Roberta Joppi; Marija Kalaba; Christina Kvalheim; Ott Laius; Irene Langner; Julie Lonsdale; Sven-Äke Lööv; Kamila Malinowska; Laura McCullagh; Ken Paterson; Vanda Markovic-Pekovic; Andrew Martin; Jutta Piessnegger; Gisbert Selke; Catherine Sermet; Steven Simoens; Cankat Tulunay; Dominik Tomek; Luka Vončina; Vera Vlahovic-Palcevski; Janet Wale; Michael Wilcock; Magdalena Wladysiuk; Menno van Woerkom; Corrine Zara; Lars L Gustafsson
Journal:  Front Pharmacol       Date:  2013-05-14       Impact factor: 5.810

4.  HTA Implementation Roadmap in Central and Eastern European Countries.

Authors:  Zoltán Kaló; Adrian Gheorghe; Mirjana Huic; Marcell Csanádi; Finn Boerlum Kristensen
Journal:  Health Econ       Date:  2016-01-14       Impact factor: 3.046

5.  Pharmaceutical lobbying and pandemic stockpiling of Tamiflu: a qualitative study of arguments and tactics.

Authors:  Andreas Vilhelmsson; Shai Mulinari
Journal:  J Public Health (Oxf)       Date:  2018-09-01       Impact factor: 2.341

6.  Drug company payments to General Practices in England: Cross-sectional and social network analysis.

Authors:  Eszter Saghy; Shai Mulinari; Piotr Ozieranski
Journal:  PLoS One       Date:  2021-12-07       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.